NCT02216279View on ClinicalTrials.gov

Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Pulmonary Hypertension
Interventions
DRUG

PulmoBind

PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).

Trial Locations (3)

H1T 1C8

Montreal Heart Institute, Montreal

Unknown

Sir Mortimer B.Davis Jewish General Hospital, Montreal

Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Québec

All Listed Sponsors
lead

Montreal Heart Institute

OTHER

NCT02216279 - Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension | Biotech Hunter | Biotech Hunter